Cargando…
The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK
BACKGROUND: Evaluating long-term prognosis is important for physicians, patients and payers. This study reports the results of a model developed to predict long-term survival for UK patients receiving second-line ipilimumab. METHODS: MDX010-20 trial data were used to predict survival for ipilimumab...
Autores principales: | Larkin, James, Hatswell, Anthony J., Nathan, Paul, Lebmeier, Maximilian, Lee, Dawn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689358/ https://www.ncbi.nlm.nih.gov/pubmed/26700304 http://dx.doi.org/10.1371/journal.pone.0145524 |
Ejemplares similares
-
Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death
por: Hatswell, Anthony J, et al.
Publicado: (2014) -
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
por: S. Ahmad, Saif, et al.
Publicado: (2015) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021) -
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014) -
Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)